简介: 男，研究员，博士。2002年在德国乌尔姆大学医学院获医学博士学位。先后在美国密苏里州立大学Columbia校区生物医学科学部，Dalton 心血管研究中心和医学院心血管内科做博士后研究。美国耶鲁大学医学院心血管内科任副研究科学家。2007年7月至2010年8月于美国密苏理州立大学Columbia校区医学院心血管内科任研究助理教授。2010年9月回国，现任四川泸州医学院药物研究中心任主任。主要从事血管生成、血栓形成、肿瘤转移微环境的研究。发表文章近40篇, 以第一作者或通信作者在Cancer Research、ATVB等国际生命科学领域高水平杂志上发表SCI研究论文14篇。美国心脏学会会员，美国心脏学会研究基金评审委员会成员 （血管生成，动脉粥样硬化和炎症组）。获美国心脏协会基金和国家自然基金。目前担任Current Angiogenesis和Frontier in Vascular Biology杂志编委和5家国际主要杂志包括ATVB，Atherosclerosis，Journal of Cellular Biochemistry的特邀审稿人。
研究方向： 血管形成、血栓形成的机理，

肿瘤转移微环境与肿瘤转移的机理。
现有课题支持：
国家自然基金面上项目 2012-01至2015-01

PAI-1在肿瘤新生血管形成中对血管稳定性的作用及机制研
美国心脏协会国家科学发展基金 2010-01至2014-12

题目：Role of vitronectin in ischemia-mediated angiogenesis
四川省教育厅重点项目 2011-01 至2013.01

题目： 基于血管内皮细胞的组织因子在血栓稳定性的作用研究
3. 泸州医学院院创新团队 2011-07 至2013-07
题目：血管生物学的基础和临床研究
学术杂志编委:
<< Current Angiogenesis>>

<< Frontiers in Vascular Biology>>
杂志审稿：
Arteriosclerosis, Thrombosis and Vascular Biology 2008-

Current Drug Targets 2009-

Atherosclerosis 2010-

Journal of Cellular Biochemistry 2010-

Expert Review of Cardiovascular Therapy 2010-
获奖和荣誉
2012 年 Reach The World 国际止血与血栓学会议

(International Society on Thrombosis and

Haemostasis XXIII Congress)

2011 年 发展中世界科学家奖(Developing World Scientists Award) 第23届

国际止血与血栓学会议(International Society on Thrombosis and

Haemostasis XXIII Congress)

2010年 美国心脏学会青年研究员奖(AHA ATVB Award for Young Investigators to Scientific Sessions)

2010年 BioFlux 生物科学公司研究创新决赛奖(Finalist 2010BioFlux Innovation Award Contest)

2008年 杰出血栓研究青年研究员决赛奖(Finalist Kenneth M. Brinkhous Young Investigator Prize in Thrombosis)

美国心脏学会青年研究员奖(AHA Merit Awards for Young Investigators)2006年 美国密苏里州立大学心血管研究博士后Poster竞赛第一名(First place Post-doctoral poster competition, Cardiovascular Day XIII of University of Missouri)

2003年 美国癌症研究协会培训学者奖(Scholar-in-training awards-American Association for Cancer Research)
大会发言:



1. Vitronectin promotes VE-cadherin internalization at cell junctions and enhances vascular

permeability. 16^th国际血管生物学会议（16^thInternational Vascular Biology, June 20-24, 2010, University of California, Los Angeles）
2. Vitronectin promotes ischemia-induced angiogenesis. 国际血栓和止血学会（The International Society on Thrombosis and Haemostasis XXII Congress, July 11-16, 2009, Boston, MA）

3. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by blocking cross-talk between _Vβ₃integrin and vascular endothelial cell growth factor receptor-2. 美国心脏学会年会（American Heart Association Scientific Sessions 2008, New Orleans, LA）
4. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. 美国心脏学会－动脉硬化，血栓，血管生物学年会（9th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, 2008, Atlanta, GA (Finalist competition)
5. PAI-1 mutant lacking protease inhibitor activity promotes atherosclerotic plaque instability in apolipoprotein E-deficient mice. 美国心脏学会－动脉硬化，血栓，血管生物学年会（9th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, 2008, Atlanta, GA）
6. C-reactive protein induces tissue factor expression in vascular smooth muscle cells.美国心脏学会－动脉硬化，血栓，血管生物学年会（7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, 2006, Denver, CO）
7. Cardiovascular Day XIII of University of Missouri, March, 2006, Columbia, MO.(Postdoctoral fellow competition)美国密苏里州立大学心血管研究
8. Reversed pharmacology of estrogen and progesterone receptor antagonists in breast cancer cells expressing increased levels of progesterone receptor B: A potential mechanism for anti-hormone resistance involving angiogenesis. 美国中西部区域分子内分泌会议（Midwest Regional Molecular Endocrinology Conference, May 19-21, 2004 Indianapolis, IN）
9. Preferential regulation of VEGF in breast cancer cells by progesterone receptor B isoform.

(Hot topic).Jensen内分泌研讨会（Jensen Symposium, December 5-7, 2003 Cincinnati, OH）
已发表研究论文:
1. Li R, Ren M, Chen N, Luo M, Zhang Z, Wu J. Vitronectin Increases Vascular Permeability by Promoting VE-Cadherin Internalization at Cell Junctions. PLoS ONE 2012; 7(5): e37195.
2. Li R, Ren M, Luo M, Chen N, Zhang Z, Luo B, Wu J. Monomeric C-reactive protein alters fibrin clot properties on endothelial cells. Thromb Res. 2012;129(5):e251-6.
3.Garg N, Goyal N, Strawn TL, Wu J, Mann KM, Lawrence DA, Fay WP. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost. 2010; 8: 1847-1854.
4. Yang Y, Wu X, Gui P, Wu J, Sheng JZ, Ling S, Braun P, Davis GE, Davis MJ. α5β1 integrin engagement increases BK channel current and Ca²⁺ sensitivity through c-Src mediated channel phosphorylation. J Biol Chem. 2010 ；285(1):131-141.

5.Wu J^*, Peng L, McMahon GA, Rabbani AB, Lawrence DA, Fay WP. Recombinant plasminogen activator Inhibitor-1 inhibits intimal hyperplasia. Arterioscler Thromb Vasc Biol. 2009; 29(10):1565-1570 ( *, as corresponding author ).
6. Hyder SM, Liang Y, Wu J. Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int. J. Cancer 2009; 125(5):1045-1053.
7. Hyder SM, Liang Y, Wu J, and Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocr Relat Cancer. 2009;16(3):809-817.
8. Wu J^*, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol. 2008; 28(4):698-704 ( *, as corresponding author). Editorial comment.
9. Zhou W, Liu Z, Wu J,Liu J, Hyder SM, Antoniou E, Lubahn DB. Identification and transcriptional activity characterization of two novel splicing isoforms of human ERRβ.

Journal of Clinical Endocrinology & Metabolism2006; 91(2):569-579.
10. Wu J, Liang Y, Nawaz Z, and Hyder SM. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: Implications for treatment resistance. International Journal of Oncology 2005; 27(6): 1647-1659.
11. Wu J, Brandt S, Hyder SM. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells. Molecular Endocrinology 2005; 19(2):312-326.
12. Liang Y, Wu J, Hyder SM. Progestins regulation of VEGF in mammary cancer cell: A connection to tumor suppressor p53. J Steroid Biochem Mol Biol. 2005; 93(2-5):173-182.
13. Wu J, Richer J, Horwitz KB and Hyder SM. Progestin-dependent induction of VEGF in human breast cancer cells: preferential regulation by progesterone receptor B.

Cancer Research 2004; 64(6): 2238-2244.
14. Babiak A, Schumm AM, Wangler, C, Loukas M, Wu J, Dombrowski S, Matuschek C, Kotzerke J, Dehio C, Waltenberger J. Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. Cardiovascular Research 2004; 61(4):789-795.